You are here: Industry Insights > monotherapy

News List

KEYTRUDA Meets Primary Trial Endpoint as Monotherapy and in Combination with Chemotherapy americanpharmaceuticalreview
April 28, 2019
KEYTRUDA Meets Primary Trial Endpoint as Monotherapy and in Combination with Chemotherapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.
FDA Approves Expanded Monotherapy Label for Merck’s Keytruda (pembrolizumab) for First-Line Treatment of NSCLC drugs
April 18, 2019
FDA Approves Expanded Monotherapy Label for Merck’s Keytruda (pembrolizumab) for First-Line Treatment of NSCLC.
The first overall survival data from the Phase 3 CheckMate -067 clinical trial worldpharmanews
April 05, 2017
Bristol-Myers Squibb Company (NYSE:BMY) today announced the first overall survival (OS) data from the Phase 3 CheckMate -067 clinical trial.
EU expands use of Revlimid to include post ACST use pharmatimes
February 28, 2017
European regulators have expanded the scope of Celgene's Revlimid to include its use as monotherapy for the maintenance treatment of adults with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation (ASCT).
Phase II study supports potential for Genentech’s Tecentriq plus Avastin for people with mRCC cphi-online
February 21, 2017
Study showed that people whose disease expressed PD-L1 and were treated with Tecentriq plus Avastin had a 36% reduction in the risk of their disease worsening